| __timestamp | BioMarin Pharmaceutical Inc. | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 4473654 |
| Thursday, January 1, 2015 | 402271000 | 8597010 |
| Friday, January 1, 2016 | 476593000 | 7910260 |
| Sunday, January 1, 2017 | 554336000 | 7304399 |
| Monday, January 1, 2018 | 604353000 | 15875961 |
| Tuesday, January 1, 2019 | 680924000 | 36881187 |
| Wednesday, January 1, 2020 | 737669000 | 44233754 |
| Friday, January 1, 2021 | 759375000 | 49628000 |
| Saturday, January 1, 2022 | 854009000 | 58183000 |
| Sunday, January 1, 2023 | 937300000 | 133710000 |
| Monday, January 1, 2024 | 1009025000 |
Unlocking the unknown
In the competitive world of biotechnology, managing operational costs is crucial for sustained growth. Over the past decade, BioMarin Pharmaceutical Inc. and Catalyst Pharmaceuticals, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses. BioMarin, a leader in rare disease therapies, has seen its SG&A costs rise steadily, peaking at nearly 937 million in 2023, reflecting a strategic investment in expanding its market reach. In contrast, Catalyst Pharmaceuticals, known for its focus on rare neurological diseases, has maintained a more conservative approach, with SG&A expenses growing from a modest 4.5 million in 2014 to 134 million in 2023. This represents a staggering 2,889% increase, highlighting Catalyst's aggressive scaling efforts. As these companies navigate the complexities of the biotech landscape, their financial strategies offer valuable insights into the balance between growth and operational efficiency.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs Catalyst Pharmaceuticals, Inc.
GSK plc vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Alnylam Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and ACADIA Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Novavax, Inc. Trends and Insights
Comparing SG&A Expenses: Jazz Pharmaceuticals plc vs Catalyst Pharmaceuticals, Inc. Trends and Insights